Effective date
Medicare changes effective August 17, 2025
11 CMS and MAC policy updates take effect on this date across 4 MAC jurisdictions. Every entry links to the government document it came from.
CMS Coverage API · 11
- LCD L39938: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — CGS
LCD-L39938CGS AdministratorsCardiologysource ↗
- LCD L39935: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — Palmetto GBA
LCD-L39935Palmetto GBAClinical Laboratorysource ↗
- LCD L39933: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Palmetto GBA
LCD-L39933Palmetto GBACardiologysource ↗
- LCD L39989: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — WPS
LCD-L39989WPSCardiologysource ↗
- LCD L39919: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Palmetto GBA
LCD-L39919Palmetto GBAHematologysource ↗
- LCD L40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — WPS
LCD-L40022WPSHematologysource ↗
- LCD L39946: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease — Noridian
LCD-L39946NoridianCardiologysource ↗
- LCD L39950: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — Noridian
LCD-L39950NoridianClinical Laboratorysource ↗
- LCD L39987: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — WPS
LCD-L39987WPSNeurologysource ↗
- LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
LCD-L40000CGS AdministratorsHematologysource ↗
- LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
LCD-L39927NoridianHematologysource ↗